7033 Five-year results of disease control and quality of life analysis of a combined hypofractionated radiation and hormone therapy regimen for intermediate-risk prostate cancer

2009 ◽  
Vol 7 (2) ◽  
pp. 416
Author(s):  
A. Roux ◽  
M. Yassa ◽  
C. Lambert ◽  
B. Fortin ◽  
M. Audet-Lapointe ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Disease Control ◽  
Hormone Therapy ◽  
Intermediate Risk ◽  
Therapy Regimen ◽  
Risk Prostate Cancer ◽  
Life Analysis ◽  
Hypofractionated Radiation

Combined Hypofractionated Radiation and Hormone Therapy for the Treatment of Intermediate-Risk Prostate Cancer

2008 ◽  
Vol 71 (1) ◽  
pp. 58-63 ◽  
Author(s):  
Michael Yassa ◽  
Bernard Fortin ◽  
Marie-Andrée Fortin ◽  
Carole Lambert ◽  
Thu Van Nguyen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Hormone Therapy ◽  
Intermediate Risk ◽  
Risk Prostate Cancer ◽  
Hypofractionated Radiation

Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer

2015 ◽  
Vol 117 (2) ◽  
pp. 252-257 ◽  
Author(s):  
Shafak Aluwini ◽  
Wendy M.H. Busser ◽  
Wendimagegn Ghidey Alemayehu ◽  
Joost L. Boormans ◽  
Wim J. Kirkels ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Intermediate Risk ◽  
High Dose Rate Brachytherapy ◽  
Risk Prostate Cancer

scholarly journals Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 278-278
Author(s):  
Jessika Contreras ◽  
Richard Wilder ◽  
Eric Albert Mellon ◽  
Tobin Joel Crill Strom ◽  
Daniel Celestino Fernandez ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Intermediate Risk ◽  
Hdr Brachytherapy ◽  
Risk Prostate Cancer ◽  
A Prospective Study

278 Background: There is little information in the literature on health-related quality-of-life (HRQOL) changes due to high-dose-rate (HDR) brachytherapy monotherapy for prostate cancer. Methods: We conducted a prospective study of HRQOL changes due to HDR brachytherapy monotherapy for low risk or favorable intermediate risk prostate cancer. Forty-nine of 84 (58%) patients who were treated between February 2011 and April 2013 completed 50 questions comprising the Expanded Prostate Cancer Index Composite (EPIC) before treatment and 6 and/or 12 months after treatment. Results: Six months after treatment, there was a significant decrease (p<0.05) in EPIC urinary, bowel, and sexual scores, including urinary overall, urinary function, urinary bother, urinary irritative, bowel overall, bowel bother, sexual overall, and sexual bother scores. By one year after treatment, all EPIC scores had increased and were not significantly different from baseline values. Conclusions: HDR brachytherapy monotherapy is well-tolerated in patients with low and favorable intermediate risk prostate cancer. Urinary, bowel, and sexual domain scores returned to close to baseline 12 months after treatment.

Sign in / Sign up

Export Citation Format

Share Document